An update on immunotherapies including chimeric antigen receptor T-cells therapy and stem cell transplantation in chronic lymphocytic leukemia

Levanto Schachter, Anthony R. Mato

Research output: Contribution to journalReview article

Abstract

Immunotherapy has become a cornerstone of therapy in oncology. For chronic lymphocytic leukemia (CLL), the treatment landscape has been changing quickly. What historically has been a disease treated with chemoimmunotherapy, and transplant in select cases, now has several newly available, targeted therapies. Many of the newly approved therapies are targeted at the B cell receptor pathway, and also have notable effect on the tumor microenvironment. Additionally, there are a number of trials looking at immune checkpoint blockade in CLL with promise noted when combined with other immune modulating therapies. Many advances have also been made in cellular therapies in CLL, including methods of allogeneic stem cells transplantation and bioengineered chimeric antigen receptor T-cells (CAR-T) which direct the immune system to kill cancer cells expressing specific antigens. The latter therapy may ultimately allow patients to avoid the risks of an allogeneic transplant while harnessing a T cell vs. leukemia effect. The future of therapy in CLL may include utilization of novel immunotherapies in combination with agents that target key pathways such a B cell receptor signaling and cell death machinery.

Original languageEnglish (US)
Pages (from-to)68-77
Number of pages10
JournalTranslational Cancer Research
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Antigen Receptors
Stem Cell Transplantation
B-Cell Chronic Lymphocytic Leukemia
Cell- and Tissue-Based Therapy
Immunotherapy
Therapeutics
B-Lymphocytes
Transplants
Tumor Microenvironment
T-Cell Antigen Receptor
Immune System
Leukemia
Cell Death
T-Lymphocytes
Antigens

Keywords

  • Adoptive
  • Antibodies
  • B-cell
  • Bone marrow transplantation
  • Chronic
  • Humanized
  • Immunotherapy
  • Leukemia
  • Lymphocytic
  • Monoclonal
  • Tumor microenvironment

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

@article{ead99de24d644aebbe3e61f579755124,
title = "An update on immunotherapies including chimeric antigen receptor T-cells therapy and stem cell transplantation in chronic lymphocytic leukemia",
abstract = "Immunotherapy has become a cornerstone of therapy in oncology. For chronic lymphocytic leukemia (CLL), the treatment landscape has been changing quickly. What historically has been a disease treated with chemoimmunotherapy, and transplant in select cases, now has several newly available, targeted therapies. Many of the newly approved therapies are targeted at the B cell receptor pathway, and also have notable effect on the tumor microenvironment. Additionally, there are a number of trials looking at immune checkpoint blockade in CLL with promise noted when combined with other immune modulating therapies. Many advances have also been made in cellular therapies in CLL, including methods of allogeneic stem cells transplantation and bioengineered chimeric antigen receptor T-cells (CAR-T) which direct the immune system to kill cancer cells expressing specific antigens. The latter therapy may ultimately allow patients to avoid the risks of an allogeneic transplant while harnessing a T cell vs. leukemia effect. The future of therapy in CLL may include utilization of novel immunotherapies in combination with agents that target key pathways such a B cell receptor signaling and cell death machinery.",
keywords = "Adoptive, Antibodies, B-cell, Bone marrow transplantation, Chronic, Humanized, Immunotherapy, Leukemia, Lymphocytic, Monoclonal, Tumor microenvironment",
author = "Levanto Schachter and Mato, {Anthony R.}",
year = "2017",
month = "1",
day = "1",
doi = "10.21037/tcr.2017.01.04",
language = "English (US)",
volume = "6",
pages = "68--77",
journal = "Translational Cancer Research",
issn = "2218-676X",
publisher = "AME Publishing Company",
number = "1",

}

TY - JOUR

T1 - An update on immunotherapies including chimeric antigen receptor T-cells therapy and stem cell transplantation in chronic lymphocytic leukemia

AU - Schachter, Levanto

AU - Mato, Anthony R.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Immunotherapy has become a cornerstone of therapy in oncology. For chronic lymphocytic leukemia (CLL), the treatment landscape has been changing quickly. What historically has been a disease treated with chemoimmunotherapy, and transplant in select cases, now has several newly available, targeted therapies. Many of the newly approved therapies are targeted at the B cell receptor pathway, and also have notable effect on the tumor microenvironment. Additionally, there are a number of trials looking at immune checkpoint blockade in CLL with promise noted when combined with other immune modulating therapies. Many advances have also been made in cellular therapies in CLL, including methods of allogeneic stem cells transplantation and bioengineered chimeric antigen receptor T-cells (CAR-T) which direct the immune system to kill cancer cells expressing specific antigens. The latter therapy may ultimately allow patients to avoid the risks of an allogeneic transplant while harnessing a T cell vs. leukemia effect. The future of therapy in CLL may include utilization of novel immunotherapies in combination with agents that target key pathways such a B cell receptor signaling and cell death machinery.

AB - Immunotherapy has become a cornerstone of therapy in oncology. For chronic lymphocytic leukemia (CLL), the treatment landscape has been changing quickly. What historically has been a disease treated with chemoimmunotherapy, and transplant in select cases, now has several newly available, targeted therapies. Many of the newly approved therapies are targeted at the B cell receptor pathway, and also have notable effect on the tumor microenvironment. Additionally, there are a number of trials looking at immune checkpoint blockade in CLL with promise noted when combined with other immune modulating therapies. Many advances have also been made in cellular therapies in CLL, including methods of allogeneic stem cells transplantation and bioengineered chimeric antigen receptor T-cells (CAR-T) which direct the immune system to kill cancer cells expressing specific antigens. The latter therapy may ultimately allow patients to avoid the risks of an allogeneic transplant while harnessing a T cell vs. leukemia effect. The future of therapy in CLL may include utilization of novel immunotherapies in combination with agents that target key pathways such a B cell receptor signaling and cell death machinery.

KW - Adoptive

KW - Antibodies

KW - B-cell

KW - Bone marrow transplantation

KW - Chronic

KW - Humanized

KW - Immunotherapy

KW - Leukemia

KW - Lymphocytic

KW - Monoclonal

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85013891047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013891047&partnerID=8YFLogxK

U2 - 10.21037/tcr.2017.01.04

DO - 10.21037/tcr.2017.01.04

M3 - Review article

AN - SCOPUS:85013891047

VL - 6

SP - 68

EP - 77

JO - Translational Cancer Research

JF - Translational Cancer Research

SN - 2218-676X

IS - 1

ER -